Key Highlights

  • Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was up 29.68% at USD 13.57 during the session on November 5, 2026, according to published market data, with roughly 3 million shares changing hands.
  • Revenue for the third quarter of 2026 climbed 44% to USD 107.2 million from USD 74.4 million, while Recorlev jumped 93% to USD 71.5 million.
  • Net income came in at USD 11.3 million, compared with USD 0.6 million a year earlier, and adjusted EBITDA reached USD 30.8 million against USD 17.4 million.
  • The company raised its full-year 2026 Revenue guidance to between USD 395 million and USD 405 million, and its 2030 outlook now sits above USD 1 billion.

Quarterly Results and Upgraded Targets

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) published its third quarter 2026 numbers on November 5, 2026, and the shares rose during that same trading day. Per published market data, the stock traded at USD 13.57, a gain of 29.68%, with a market Capitalization close to USD 2.47 billion. Total revenue reached USD 107.2 million, a 44% increase from USD 74.4 million, while Net Income was USD 11.3 million versus USD 0.6 million. The 2026 revenue forecast moved up to USD 395 million through USD 405 million, and the 2030 total revenue target was lifted to more than USD 1 billion from roughly USD 750 million. Chairman and chief executive John Shannon said the firm is now positioned to surpass USD 1 billion by 2030.

Revenue Mix and Cash Position

Recorlev, a Cushing's syndrome therapy, brought in USD 71.5 million, up 93%, and has become the primary engine of expansion. Gvoke, the ready-to-use glucagon product, dropped 14% to USD 21.7 million; that decline includes a one-time gross-to-net adjustment of around USD 4 million, meaning a revision to rebates and discounts that lowers reported sales. Keveyis increased 9% to USD 13.0 million. Adjusted EBITDA, which strips out interest, taxes, Depreciation and some non-cash items, came to USD 30.8 million. For the first nine months, revenue totaled USD 282.5 million, up 37%, but the net loss reached USD 17.6 million due to a one-time non-cash charge of approximately USD 30.8 million linked to the exchange of the 2028 convertible notes. At quarter end cash stood at USD 131.1 million and long-term Debt at USD 189.7 million, following the retirement of those notes on July 15, 2026.

Concentration and Execution Hazards

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is now heavily dependent on Recorlev, which accounts for about two-thirds of quarterly revenue by simple division, so changes in pricing, competition or reimbursement could hit results hard. Gvoke's decline reminds investors that not every product is expanding. Long-term debt of USD 189.7 million is significant relative to cash of USD 131.1 million, and published market data shows trailing Earnings of negative USD 0.10 per share, meaning profitability is only recent on a quarterly basis. A 2030 goal above USD 1 billion is an aspiration rather than a forecast backed by contracts, and a rally of this scale can give back gains. Investors should monitor Recorlev prescription trends, signs of Gvoke stabilizing, debt reduction and the fourth quarter report.

Where Things Stand

The 29.68% move in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is linked to concrete developments: revenue up 44%, a turn to USD 11.3 million of quarterly net income, a higher 2026 forecast and a 2030 goal above USD 1 billion. These results support a strong response, although a jump of this magnitude also builds in further Recorlev gains. Debt, product concentration and the Gvoke slide act as the main offsets, and the nine-month net loss signals that profit is still a new development. The next events to track are the fourth quarter report and any revision to the long-term goals.